Form 8-K - Current report:
SEC Accession No. 0001104659-26-074067
Filing Date
2026-06-15
Accepted
2026-06-15 16:30:49
Documents
13
Period of Report
2026-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2617889d1_8k.htm   iXBRL 8-K 70376
2 EXHIBIT 3.1 tm2617889d1_ex3-1.htm EX-3.1 154668
3 EXHIBIT 10.1 tm2617889d1_ex10-1.htm EX-10.1 82897
  Complete submission text file 0001104659-26-074067.txt   521294

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA qure-20260610.xsd EX-101.SCH 3011
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE qure-20260610_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qure-20260610_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2617889d1_8k_htm.xml XML 3245
Mailing Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 261091279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)